Clinical trial of long acting methylphenidate in amphetamine addicts with Attention Deficit Hyperactivity Disorder (ADHD)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN81602628

Enrollment

Registered

2008-04-21

Start date

2006-02-14

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficit hyperactivity disorder Mental and Behavioural Disorders Attention deficit hyperactivity disorder

Interventions

Participants are required to stay abstinent of any substance for minimum two weeks prior the inclusion. Intervention group: Long acting methylphenidate (Concerta®) for 12 weeks, starting dose of 18

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male or female 18 to 65 years 2. Written consent 3. Amphetemine (amph) dependence according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) 4. Used apmh on minimum 10 days during the year before inclusion 5. ADHD according to DSM-IV 6. Living in Stockholm area

Exclusion criteria

Exclusion criteria: 1. Dependence (current or past) of opioids, cannabis or benzodiazepines 2. Have used opioids within 3 months before screening 3. Other serious psychiatric conditions such as suicidality or psychosis 4. Current treatment with benzodiazepines, antidepressants or neuroleptics 5. Heart condition or stroke or any other medical condition that is considered a risk 6. Pregnancy or breastfeeding 8. IQ <75

Design outcomes

Primary

Measure	Time frame
Reduction in self rated ADHD symptoms, assessed using the Conners' Adult ADHD Rating Scale (CAARS) at baseline and once a week for 12 weeks	—

Secondary

Measure	Time frame
1. Reduction in drug use: urine toxicology at baseline and weeks 4, 8 and 12 2. Observer rated ADHD symptoms, assessed using CAARS at baseline and once a week for 12 weeks 3. Psychiatric symptoms at baseline and weeks 4, 8 and 12 3.1. Self rated craving assessed with Tiffany craving scale 3.2. Change in symptoms of depression and anxiety assessed with Becks inventories 3.3. Stroop test (test of selective attention)	—

Measure

Time frame

1. Reduction in drug use: urine toxicology at baseline and weeks 4, 8 and 12 2. Observer rated ADHD symptoms, assessed using CAARS at baseline and once a week for 12 weeks 3. Psychiatric symptoms at baseline and weeks 4, 8 and 12 3.1. Self rated craving assessed with Tiffany craving scale 3.2. Change in symptoms of depression and anxiety assessed with Becks inventories 3.3. Stroop test (test of selective attention)

—

Countries

Sweden

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026